Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Atlassian
TEAM
|
+$350M |
| 2 |
NVIDIA
NVDA
|
+$308M |
| 3 |
Mercado Libre
MELI
|
+$305M |
| 4 |
Roblox
RBLX
|
+$300M |
| 5 |
NIO
NIO
|
+$280M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABMD
Abiomed Inc
ABMD
|
+$1.21B |
| 2 |
Meta Platforms (Facebook)
META
|
+$552M |
| 3 |
Illumina
ILMN
|
+$485M |
| 4 |
Ferrari
RACE
|
+$316M |
| 5 |
Arthur J. Gallagher & Co
AJG
|
+$294M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.94% |
| 2 | Consumer Discretionary | 24.48% |
| 3 | Technology | 18.24% |
| 4 | Communication Services | 10.28% |
| 5 | Financials | 7.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
BioCryst Pharmaceuticals
BCRX
$2.4B
| $19.4K | ﹤0.01% |
1,687
| – | – |
|
352
Johnson & Johnson
JNJ
$625B
| $19.1K | ﹤0.01% |
108
+9
| +9% | +$1.55K |
|
353
Boston Omaha
BOC
$436M
| $17.9K | ﹤0.01% |
676
+147
| +28% | +$3.85K |
|
354
Walmart Inc
WMT
$890B
| $17.9K | ﹤0.01% |
378
+75
| +25% | +$3.56K |
|
355
Regenxbio
RGNX
$708M
| $17.1K | ﹤0.01% |
752
| – | – |
|
|
AYX
356
DELISTED
Alteryx Inc
AYX
| $17K | ﹤0.01% |
336
| – | – |
|
357
Blackrock
BLK
$176B
| $17K | ﹤0.01% |
24
+3
| +14% | +$2K |
|
358
Coherent
COHR
$74.2B
| $16.7K | ﹤0.01% |
477
| – | – |
|
359
Nutanix
NTNX
$16.9B
| $16.6K | ﹤0.01% |
637
+74
| +13% | +$2.02K |
|
|
SGEN
360
DELISTED
Seagen Inc. Common Stock
SGEN
| $16.4K | ﹤0.01% |
128
| – | – |
|
361
Merck
MRK
$318B
| $16.4K | ﹤0.01% |
148
| – | – |
|
362
Kforce
KFRC
$1.06B
| $16.2K | ﹤0.01% |
295
| – | – |
|
363
Church & Dwight Co
CHD
$24.5B
| $16K | ﹤0.01% |
199
+20
| +11% | +$1.53K |
|
364
Medifast
MED
$141M
| $15.9K | ﹤0.01% |
138
+17
| +14% | +$1.98K |
|
365
Brunswick
BC
$5.28B
| $15.8K | ﹤0.01% |
219
| – | – |
|
366
Procept Biorobotics
PRCT
$1.17B
| $15.6K | ﹤0.01% |
376
| – | – |
|
367
Cytokinetics
CYTK
$10.4B
| $15.6K | ﹤0.01% |
340
| – | – |
|
368
Goodyear
GT
$1.85B
| $15.5K | ﹤0.01% |
1,525
| – | – |
|
369
J&J Snack Foods
JJSF
$1.71B
| $15.4K | ﹤0.01% |
103
+20
| +24% | +$2.97K |
|
370
Expedia Group
EXPE
$37.3B
| $15.4K | ﹤0.01% |
176
| – | – |
|
371
Dollar General
DG
$27.9B
| $15.3K | ﹤0.01% |
62
| – | – |
|
372
A.O. Smith
AOS
$8.7B
| $15.1K | ﹤0.01% |
263
| – | – |
|
373
PagerDuty
PD
$902M
| $15K | ﹤0.01% |
565
| – | – |
|
374
Marriott International
MAR
$92.3B
| $14.9K | ﹤0.01% |
100
| – | – |
|
375
Enanta Pharmaceuticals
ENTA
$400M
| $14.8K | ﹤0.01% |
318
| – | – |
|
Similar funds
Baillie Gifford & Co's Q4 2022 Portfolio in Review
As of Q4 2022, Baillie Gifford & Co held 500 positions worth $96B, down 1.1% from $97B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Baillie Gifford & Co's Q4 2022 filing shows 14 new, 150 increased, 126 reduced and 12 closed positions. Its largest new stake was Eaton: 1,452,086 shares worth $228M. The largest sale was Abiomed Inc, an estimated $1.21B.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Technology.
- Baillie Gifford & Co's largest Q4 2022 buy was Eaton: 1,452,086 shares worth $228M.
- Baillie Gifford & Co added most to Atlassian in Q4 2022, an estimated $350M increase.
- Baillie Gifford & Co's biggest Q4 2022 reduction was Abiomed Inc, cutting an estimated $1.21B.
- Baillie Gifford & Co fully exited Li Auto in Q4 2022, selling an estimated $134M.
- Baillie Gifford & Co's ten largest holdings make up 36% of its $96B portfolio in Q4 2022.
- Baillie Gifford & Co opened 14 new positions and closed 12 in Q4 2022.
- Baillie Gifford & Co's portfolio value fell 1.1% quarter-over-quarter to $96B.
Based on Baillie Gifford & Co's 13F filing for Q4 2022, filed 24 Jan 2023.